科匯股份(688681.SH):變更保薦代表人為陳鈺、唐彬
格隆匯11月5日丨科匯股份(688681.SH)公佈,國海證券作為公司首次公開發行股票並在科創板上市的保薦機構,原委派林舉、李剛作為公司持續督導的保薦代表人。持續督導期限自首次公開發行股票並在科創板上市之日起至2024年12月31日止。
現林舉、李剛因工作變動,不能繼續履行對公司的持續督導職責。為保證持續督導工作的有序進行,國海證券委派陳鈺、唐彬接替林舉、李剛對尚未完結的持續督導工作履行相應職責。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.